Evidence map›Paper›PMID 26437062›Full record

Trial reportBone marrow transplantation2016

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

E Klyuchnikov, U Bacher, K Woo Ahn, J Carreras, N M Kröger, P N Hari, G H Ku, E Ayala, A I Chen, Y-B Chen and 16 more

Open access · bronzeAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Where does transplant fit in the age of targeted therapies?Hematology. American Society of Hematology. Education Program · 2019
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 5 countries.

E KlyuchnikovDepartment for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany.
U BacherDepartment for Hematology/Oncology, Georg August University Göttingen, Göttingen, Germany.
K Woo AhnCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J CarrerasCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
N M KrögerDepartment for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany.
P N HariCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
G H KuDivision of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, CA, USA.
E AyalaDepartment of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
A I ChenOregon Health and Science University, Portland, OR, USA.
Y-B ChenDivision of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
J B CohenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
C O FreytesSouth Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
R P GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College of London, London, UK.
R T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
M A Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
H M LazarusSeidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
R MartinoDivision of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
A MussettiSC Ematologia e Trapianto Midollo Osseo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
B N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
H C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.
S Z UsmaniDepartment of Hematology - Medical Oncology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
P H WiernikOur Lady of Mercy Medical Center, Bronx, NY, USA.
B WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA.
S M SmithSection of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
A SuredaServei d'Hematologia, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
M HamadaniCIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USMoffitt Cancer Center · USUniversity Cancer Center Hamburg · DEBaylor College of Medicine · USCarolinas Healthcare System · USEmory University · USFondazione IRCCS Istituto Nazionale dei Tumori · ITHospital de Sant Pau · ESImperial College London · GBInstitut Català d'Oncologia · ESLady of Mercy Medical Center · USMassachusetts General Hospital · USOregon Health & Science University · USSeattle Cancer Care Alliance · USSouth Texas Veterans Health Care System · USUniversity Hospitals Seidman Cancer Center · USUniversity of California, San Diego · USUniversity of Chicago · USUniversity of Göttingen · DEVanderbilt University Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA076518NHLBI NIH HHS 5U10HL069294NHLBI NIH HHS U10 HL069294PHS HHS HHSH250201200016C
6 · The paper itself

Abstract

Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P<0.001), 61% vs 20% (P<0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR)=0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR=3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR=0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedAllograftsAutograftsDisease-Free SurvivalFemaleHumansLymphoma, FollicularMaleMiddle AgedSurvival RateTime Factors

Identifiers

PMID26437062
PMCPMC4703480
OpenAlexW2189683173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.